

FINAL STUDY REPORT

STUDY TITLE

Determination of Available Chlorine, pH and Hypochlorous Acid Concentration

PRODUCT IDENTITY

Ultra-Lyte UL-15, UL-16, UL-17, UL-18 and UL-19

DATA REQUIREMENTS

U.S. Environmental Protection Agency, Office of Prevention, Pesticides, and Toxic Substances (OPPTS), Product Properties Test Guidelines

AUTHOR

Amy S. Jeske, B.S. Study Director

STUDY COMPLETION DATE

April 29, 2010

PERFORMING LABORATORY

ATS Labs 1285 Corporate Center Drive, Suite 110 Eagan, MN 55121

SPONSOR

Clarentis LLC 23969 NE SR3, Suite G # 143 Belfair, WA 98528

SPONSOR REPRESENTATIVE

Plains ECA Solutions RR1 Decker Manitoba R0M 0K0 Canada

PROJECT NUMBER

A09183

Page 1 of 23

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10 (d) (1) (A), (B), or (C).

Company:	Clarentis LLC			
Company Agent:	-			
		Title		
	 		Date:	
		Signature		

Clarentis LLC Page 3 of 23

GOOD LABORATORY PRACTICE STATEMENT

The study referenced in this report was conducted in compliance with U.S. Environmental Protection Agency Good Laboratory Practice (GLP) regulations set forth in 40 CFR Part 160.

The studies not performed by or under the direction of ATS Labs are exempt from this Good Laboratory Practice Statement and include: characterization and stability of the compounds that are not outlined in this protocol.

Submitter:	Date:
Sponsor:	Date:
Study Director: Study Director	Date: 4/29/10

Clarentis LLC ATS & L/

QUALITY ASSURANCE UNIT SUMMARY

Study: Determination of Available Chlorine, pH and Hypochlorous Acid Concentration

The objective of the Quality Assurance Unit is to monitor the conduct and reporting of nonclinical laboratory studies. These studies have been performed under Good Laboratory Practice regulations (40 CFR Part 160) and in accordance to standard operating procedures and standard protocols. The Quality Assurance Unit maintains copies of study protocols and standard operating procedures and has inspected this study on the dates listed below. Studies are inspected at time intervals to assure the integrity of the study.

Phase Inspected	Date	Study Director	Management
Critical Phase	March 12, 2010	March 12, 2010	A 20, 2040
Final Report	April 27, 2010	April 27, 2010	April 28, 2010

The findings of these inspections have been reported to management and the Study Director.

Quality Assurance Auditor:

Date: 4/28/6

TABLE OF CONTENTS

Title Page	. 1
Statement of No Data Confidentiality Claims	. 2
Good Laboratory Practice Statement	. 3
Quality Assurance Unit Summary	4
Table of Contents	5
Study Personnel	6
General Study Information	7
Test Substance Identity	7
Study Dates	7
Objective	7
Test History	8
Test Priciple	8
Test Method	8
Results	9
Calculations	9
Protocol Changes	9
Study Retention	10
References	10
Analysis And Conclusion	11
Table 1: pH Results	12
Table 2: Titration Results	12
Table 3: Calculated Results	13
Fable 4: Supplemental Data for Lots Not Used in Study	14
Test Protocol	15

STUDY PERSONNEL

STUDY DIRECTOR:

Amy S. Jeske, B.S.

Professional personnel involved:

Scott R. Steinagel, B.S. Anne Stemper, B.S.

Adam Pitt, B.S. Peter Toll, B.S.

Erin Hawkinson, B.S.

- Manager, Microbiology Laboratory Operations - Research Scientist I

- Research Assistant II

- Research Assistant II

- Research Assistant I

Page 7 of 23



STUDY REPORT

GENERAL STUDY INFORMATION

Study Title:

Determination of Available Chlorine, pH and Hypochlorous Acid Concentration

Project Number:

A09183

Protocol Number:

CLS01030210.CUST.1

Sponsor:

Clarentis LLC

23969 NE SR3, Suite G #143

Belfair, WA 98528

Sponsor

Plains ECA Solutions RR1 Decker Manitoba

R0M 0K0 Canada

Test Facility:

Representative:

ATS Labs

1285 Corporate Center Drive, Suite 110

Eagan, MN 55121

TEST SUBSTANCE IDENTITY

Test Substance Name: Ultra-Lyte

Lot/Batch(s):

UL-15, UL-16, UL-17, UL-18 and UL-19

Test Substance Characterization

Test substance characterization not outlined in this protocol is the responsibility of the Sponsor.

STUDY DATES

Date of Test Substance Preparation:

March 11, 2010

Study Initiation Date:

March 9, 2010

Experimental Start Date:

March 11, 2010

Experimental End Date:

March 12, 2010

Study Completion Date:

April 29, 2010

OBJECTIVE

The objective of this study was to determine the (free) available chlorine, pH and to calculate the hypochlorous acid concentration of a Sponsor's product.



TEST HISTORY

The test substances used in this protocol were prepared at ATS Labs on March 11, 2010. The initial samples Ultra-Lyte lots UL-10, UL-11, UL-12, UL-13 and UL-14 were expected to contain approximately 525 ppm of available chlorine when they were supplied to ATS Labs. Upon titration. ATS determined that UL-10 was more concentrated than indicated by the Sponsor. At that time, the Sponsor decided to replace Ultra-Lyte lots UL-10, UL-11, UL-12, UL-13 and UL-14, with new samples also prepared at ATS Labs (see Amendment 1). The results of the pH assessment for Ultra-Lyte lots UL-10, UL-11, UL-12, UL-13 and UL-14 and partial titration of Ultra-Lyte lot UL-10 can be found in Table 4: Supplemental Data for Lots Not Used in Study.

TEST PRINCIPLE

The concentration of available chlorine in the test substance was determined by a colorimetric sodium thiosulfate titration method. Potassium iodide (KI) and sulfuric acid (H₂SO₄) are added to an aliquot of test substance and mixed. The solution was then titrated with sodium thiosulfate and starch indicator was added to enhance the visualization of the endpoint. The pH of each test substance lot was determined in triplicate at 25±1°C using a calibrated pH probe capable of measuring pH to ±0.05. The hypochlorous acid concentration of each test substance lot was calculated using the average pH and available chlorine as determined in testing.

TEST METHOD

Based on the Sponsor's expected concentration range, triplicate samples of each test substance lot were transferred to individual vessels and were titrated. The weight of sample transferred to each vessel was determined by the following calculation:

Weight of sample (in grams) = $(N \text{ of titrant}) \times (15 \text{ mL titrant}) \times (\sim 36 \text{ g Cl}^*/\text{Eq}) \times 1000$ (Theoretical ppm of NaOCl solution to be titrated)

*NOTE: This equation was used when analyzing for NaOCI or available chlorine. An approximate molecular weight for either available chlorine or NaOCI was included.

The approximate amount of sample was transferred, as calculated above, to three clean vessels. (An alternate number of replicates were performed per Sponsor's request.) 10.0 mL of 10% KI solution and 10.0 mL of 10% H₂SO₄ was transferred to each vessel and the vessels were mixed. The buret was filled with the titrant, ~0.1N Sodium thiosulfate (0.1003N). The titrant was added to the vessel, mixing with additions. The titrant continued to be added until a pale yellow color emerged. Once the pale yellow color was achieved, a four drops of starch indicator was added and mixed. A dark purple and/or blackish color emerged. The titration continued until a clear endpoint was achieved. The volume of titrant added from the buret was read. This procedure was repeated for all remaining vessels. The actual ppm value was determined by averaging the ppm results from each replicate. Results were rounded to the nearest whole ppm.

Hq

The test substances were prepared on site at ATS and tested as Ready-To-Use (RTU). Three replicate pH determinations were made for each lot of test substance. The pH measurements were conducted at room temperature using a temperature compensating probe and a pH meter capable of measuring pH to ± 0.05. At least two NIST traceable reference buffers, 4.00, 7.00 and 10.00, were used to calibrate the pH meter prior to sample analysis.

RESULTS

The results of the chemical tests from the test procedure section of this protocol are reported in Tables 1-

CALCULATIONS

To calculate the available chlorine concentration (FAC):

Once calculated, the ppm values for replicate titrations may be averaged and reported.

N of titrant = Normality of the Sodium thiosulfate using four significant digits (i.e. 0.1000N)

To calculate the percent hypochlorous acid (HOCL):

% HOCL =
$$100 \times [1 + K_i/(H^{\dagger})]^{-1}$$

Where: K_i is the dissociation constant of HOCL at 20°C or 2.621 x 10⁻⁸ mol/L (H⁺) is the negative log₁₀ of the average pH value per lot

To calculate the percent of available HOCL:

STATISTICAL METHODS: Arithmetic averages and standard deviation were used when applicable.

PROTOCOL CHANGES

Protocol Amendments:

1.1 Per Sponsor's request, this protocol is amended to include a Sponsor Representative. The name and address of the Sponsor Representative are as below:

> Plains ECA Solutions RR1 Decker Manitoba R0M 0K0 Canada

- 1.2 Per Sponsor's request, this protocol is amended to replace the test substance Ultra-Lyte UL-10, UL-11, UL-12, UL-13 and UL-14 with Ultra-Lyte UL-15, UL-16, UL-17, UL-18 and UL-19
- This protocol is amended to correct an error in the calculation for determining the percent of Available HOCI. The equation should read as below:



Protocol Deviations:

Under the Test Principle section of the protocol, it states that the pH of the test substance will be determined using triplicate samples per lot which have been equilibrated to 25±1°C and a calibrated pH probe capable of measuring pH to ±0.05. The temperature range for this determination was inadvertently left in the protocol. For this study, the pH of each test substance was determined at room temperature, which is a deviation from what is stated in the protocol. This protocol deviation did not have an impact on the outcome of the study and is considered acceptable because the pH of each test substance was determined using a temperature compensating probe and the appropriate NIST traceable buffers were also used.

STUDY RETENTION

Record Retention

All of the original raw data developed exclusively for this study shall be archived at ATS Labs, 1285 Corporate Center Drive, Suite 110, Eagan, MN 55121. These original data include, but are not limited to, the following:

- 1. Certified copy of final study report.
- 2. Original signed protocol.
- 3. Any protocol amendments/deviation notifications.
- 4. All handwritten raw data for control and test substances including, but not limited to, notebooks, data forms and calculations.
- 5. All measured data used in formulating the final report.
- 6. Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
- 7. Study specific SOP deviations made during the study.

Test Substance Retention

The test substances will be discarded following study completion per Sponsor approved protocol. It is the responsibility of the Sponsor to retain a sample of the test material.

REFERENCES

- 1. ATS Labs SOP # CGT-0090, "Sodium Hypochlorite Preparation and Sodium Hypochlorite / Available Chlorine Determination", current version.
- 2. Code of Federal Regulations, 40 CFR 158.
- 3. Eaton AD, et. al. 2005. Standard Methods For the Examination of Water and Wastewater, 21st edition. Washington DC: American Public Health Association.
- 4. Handbook of Chemistry and Physics, CRC Publishing Co., Boca Raton, FL, 58th Edition.
- 5. ASTM E70-97, "Standard Test method for pH of Aqueous Solutions with the Glass Electrode", 2002.
- 6. ATS Labs SOP # PCT-8030, "pH Measurement", current version.

Page 11 of 23



ANALYSIS AND CONCLUSION

Ultra-Lyte, UL-15, was determined to have an average free available chlorine of 0.0546%, an average hypochlorous acid of 94.1%, an average available hypochlorous acid of 0.0514% and an average pH of 6.38.

Ultra-Lyte, UL-16, was determined to have an average free available chlorine of 0.0539%, an average hypochlorous acid of 94.3%, an average available hypochlorous acid of 0.0508% and an average pH of 6.36.

Ultra-Lyte, UL-17, was determined to have an average free available chlorine of 0.0539%, an average hypochlorous acid of 94.5%, an average available hypochlorous acid of 0.0509% and an average pH of 6.35.

Ultra-Lyte, UL-18, was determined to have an average free available chlorine of 0.0526%, an average hypochlorous acid of 93.8%, an average available hypochlorous acid of 0.0493% and an average pH of 6.40.

Ultra-Lyte, UL-19, was determined to have an average free available chlorine of 0.0544%, an average hypochlorous acid of 94.5%, an average available hypochlorous acid of 0.0514% and an average pH of 6.35.

In the opinion of the Study Director, there were no circumstances that may have adversely affected the quality or integrity of the data.

The use of the ATS Labs name, logo or any other representation of ATS Labs without the written approval of ATS Labs is prohibited. In addition, ATS Labs may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express written permission of ATS Labs.

Page 12 of 23



TABLE 1: pH RESULTS

Sample	Run	рН	Average pH
1114 1.4-	1	6.39	
Ultra-Lyte UL-15	2	6.37	6.38
OL-10	3	6.38	
I litro I vito	1	6.34	
Ultra-Lyte UL-16	2	6.37	6.36
OL10	3	6.37	
I likus I vets	1	6.34	
Ultra-Lyte UL-17	2	6.36	6.35
OL*17	3	6.36	
I litura I vota	1	6.41	
Ultra-Lyte UL-18	2	6.39	6.40
OE-10	3 6.41	6.41	
i litro I veto	1	6.33	
Ultra-Lyte - UL-19 -	2	6.35	6.35
OL 10	3	6.36	

TABLE 2: TITRATION RESULTS

Samp	le	Sample Mass (g)	Volume of Titrant Used to Reach the End Point (mL)	ppm Free Available Chlorine	Average ppm Free Available Chlorine
I likan 1 saka	Run # 1	108.25	16.8	552	
Ultra-Lyte UL-15	Run # 2	99.84	15.3	545	546
OL-10	Run # 3	99.73	15.2	542	
1114 1 - 4 -	Run # 1	99.99	15.2	541	
Uitra-Lyte UL-16	Run # 2	100.09	15.3	544	539
01-10	Run # 3	99.07	14.8	531	
1114	Run # 1	99.53	15.1	539	
Ultra-Lyte UL-17	Run # 2	99.82	15.2	541	539
OL-17	Run # 3	99.84	15.1	538	
	Run # 1	99.73	14.7	524	
Ultra-Lyte UL-18	Run # 2	99.96	14.8	526	526
02-10	Run # 3	99.24	14.7	527	
1.114 14	Run # 1	100.06	15.3	544	
Ultra-Lyte UL-19	Run # 2	100.26	15.3	543	544
OL-19	Run # 3	100.02	15.3	544	

ppm = parts per million

Page 13 of 23

Protocol Number: CLS01030210.CUST.1



TABLE 3: CALCULATED RESULTS

Sample	9	Average Percent Free Available Chlorine	Average pH	Average Percent Hypochlorous Acid	Average Percent Available Hypochlorous Acid
Ultra-Lyte	Run # 1				
UL-15	Run # 2	0.0546	6.38	94.1	0.0514
02 10	Run # 3				
Liltro Luto	Run # 1				
Ultra-Lyte UL-16	Run # 2	0.0539	6.36	94.3	0.0508
01-10	Run#3				
1 litura I vita	Run # 1				
Ultra-Lyte UL-17	Run # 2	0.0539	6.35	94.5	0.0509
OL-17	Run#3				
I litera I vala	Run#1				
Ultra-Lyte UL-18	Run # 2	0.0526	6.40	93.8	0.0493
02-10	Run # 3				
1114	Run # 1				
Ultra-Lyte UL-19	Run # 2	0.0544	6.35	94.5	0.0514
01-19	Run # 3				

Page 14 of 23



TABLE 4: SUPPLEMENTAL DATA FOR LOTS NOT USED IN STUDY

Sample	Run	рН		Average pH	
Ultra-Lyte	1	6.16			
UL-10	2	6.16		6.17	
02.0	3	6.19			
Ultra-Lyte	1	6.22			
UL-11	2	6.22		6.23	
<u> </u>	3	6.26			
Ultra-Lyte	1	6.23			
UL-12	2	6.24		6.24	
V = 1 =	3	6.24			
Ultra-Lyte	1	6.24			
UL-13	2	6.23		6.24	
	3	6.24			
Ultra-Lyte	1	6.28		6.29	
UL-14	2 ·	6.28			
	3	6.31			
Sample	Run	Sample Mass (g)	Volume of Titrant Used to Reach the End Point (mL)	ppm Free Available Chlorine	
Ultra-Lyte	1	41.63	7.6	649	
UL-10	2	40.77	7.4	645	

ppm = parts per million

Clarentis LLC Page 15 of 23



ATSLABS

AMENDMENT TO GLP TEST PROTOCOL

Amendment No.:

2

Effective Date:

3/16/10

Sponsor:

Clarentis LLC

23969 NE SR3, Suite G # 143

Belfair, WA 98528

INITIALS IL DATE 4-28-10

Sponsor Representative:

Plains ECA Solutions RR1 Decker Manitoba R0M 0K0 Canada

Test Facility:

ATS Labs

1285 Corporate Center Drive, Suite 110

Eagan, MN 55121

Protocol Title:

Determination of Available Chlorine, pH and

Hypochlorous Acid Concentration

ATS Labs Protocol Number:

CLS01030210.CUST.1

ATS Labs Project Number:

A09183

Modifications to Protocol:

This protocol is amended to correct an error in the calculation for determining the percent of Available HOCl. The equation should read as below:

% Available HOCI = <u>% FAC x %HOCI</u> 100

Changes to the protocol are acceptable as noted.

Study Director

Date

Clarentis LLC Page 16 of 23

Protocol Number: CLS01030210.CUST.1

ATSLABS

ATS & LABS

AMENDMENT TO GLP TEST PROTOCOL

Amendment No.:

1

Effective Date:

3/11/10

Sponsor:

Clarentis LLC

23969 NE SR3, Suite G # 143

Belfair, WA 98528

Test Facility:

ATS Labs

1285 Corporate Center Drive, Suite 110

Eagan, MN 55121

Protocol Title:

Determination of Available Chlorine, pH and

Hypochlorous Acid Concentration

ATS Labs Protocol Number:

CLS01030210.CUST.1

ATS Labs Project Number:

A09183

Modifications to Protocol:

Per Sponsor's request, this protocol is amended to include a Sponsor Representative.
 The name and address of the Sponsor Representative are as below:

Plains ECA Solutions RR1 Decker Manitoba R0M 0K0 Canada

2. Per Sponsor's request, this protocol is amended to replace the test substance Ultra-Lyte UL-10, UL-11, UL-12, UL-13 and UL-14 with Ultra-Lyte UL-15, UL-16, UL-17, UL-18 and UL-19

Changes to the protocol are acceptable as noted.

Sponsor


Date

Study Director

Date

Clarentis LLC Page 17 of 23





ATS & LABS

PROTOCOL

Determination of Available Chlorine, pH and Hypochlorous Acid Concentration

PROTOCOL NUMBER

CLS01030210.CUST.1

PREPARED FOR

Clarentis LLC 23969 NE SR3, Suite G # 143 Belfair, WA 98528

PERFORMING LABORATORY

ATS Labs 1285 Corporate Center Drive, Suite 110 Eagan, MN 55121

PREPARED BY

Amy S. Jeske, B.S. Manager, Microbiology Operations

DATE

March 2, 2010

PROPRIETARY INFORMATION

THIS DOCUMENT IS THE PROPERTY OF AND CONTAINS PROPRIETARY INFORMATION OF ATS LABS. NEITHER THIS DOCUMENT, NOR INFORMATION CONTAINED HEREIN IS TO BE REPRODUCED OR DISCLOSED TO OTHERS, IN WHOLE OR IN PART, NOR USED FOR ANY PURPOSE OTHER THAN THE PERFORMANCE OF THIS WORK ON BEHALF OF THE SPONSOR, WITHOUT PRIOR WRITTEN PERMISSION OF ATS LABS.

Custom

Page 1 of 7

1285 Corporate Center Drive, Suite 110 • Eagan, MN 55121 • 877.287.8378 • 651.379.5510 • Fax: 651.379.5549

WI 9 % LWD9

Clarentis LLC Page 18 of 23



Protocol Number: CLS01030210.CUST.1

Clarentis LLC Page 2 of 7 **ATS**LABS

Determination of Available Chlorine, pH and Hypochlorous Acid Concentration

SPONSOR:

Clarentis LLC

23969 NE SR3, Suite G # 143

Belfair, WA 98528

TEST FACILITY:

ATS Labs

1285 Corporate Center Drive, Suite 110

Eagan, MN 55121

PURPOSE

The purpose of this study is to determine the (free) available chlorine, pH and to calculate the hypochlorous acid concentration of a Sponsor's product.

TEST SUBSTANCE CHARACTERIZATION

The Sponsor will be responsible for all test substance characterization that is not outlined in this protocol.

SCHEDULING AND DISCLAIMER OF WARRANTY

Experimental start dates are generally scheduled on a first-come/first-serve basis once ATS Labs receives the Sponsor approved/completed protocol, signed fee schedule and corresponding test substance(s). Based on all required materials being received at this time, the <u>proposed</u> experimental start date is March 11, 2010. Verbal results may be given upon completion of the study with a written report to follow on the <u>proposed</u> completion date of April 2, 2010. To expedite scheduling, please be sure all required paperwork and test substance documentation is complete/accurate upon arrival at ATS Labs.

If a test must be repeated, or a portion of it, due to failure by ATS Labs to adhere to specified procedures, it will be repeated free of charge. If a test must be repeated, or a portion of it, due to failure of internal controls, it will be repeated free of charge. "Methods Development" fees shall be assessed, however, if the test substance and/or test system require modifications due to complexity and difficulty of testing.

If the Sponsor requests a repeat test, they will be charged for an additional test.

Neither the name of ATS Labs or any of its employees are to be used in advertising or other promotion without written consent from ATS Labs.

The Sponsor is responsible for any rejection of the final report by the United States FDA or EPA concerning report format, pagination, etc. To prevent rejection, Sponsor should carefully review the ATS Labs final report and notify ATS Labs of any perceived deficiencies in these areas before submission of the report to the regulatory agency. ATS Labs will make reasonable changes deemed necessary by the Sponsor, without altering the technical data.

TEST PRINCIPLE

The concentration of available chlorine in the test substance will be determined by a colorimetric sodium thiosulfate titration method. Potassium iodide (KI) and sulfuric acid (H_2SO_4) are added to an aliquot of test substance and mixed. The solution is then titrated with sodium thiosulfate. Starch indicator is added to enhance the visualization of the endpoint. The pH of the test substance will be determined using triplicate samples per lot which have been equilibrated to $25\pm1^{\circ}C$ and a calibrated pH probe capable of measuring pH to \pm 0.05. The hypochlorous acid concentration will be calculated using the average pH and available chlorine as determined in testing.

- Proprietary Information -

Page 19 of 23

Protocol Number: CLS01030210.CUST.1

Clarentis LLC ATS LA

Protocol Number: CLS01030210,CUST.1

Clarentis LLC Page 3 of 7 ATS LABS

TEST PROCEDURE

Based on the Sponsor's expected concentration range, triplicate samples (or other specified number) of each test substance will be transferred to individual vessels and will be titrated. The weight of sample to be transferred to each vessel is determined by the following calculation:

Weight of sample (in grams) = (N of titrant) x (15 mL titrant) x (-36 g Cl*/Eq) x 1000 (Theoretical ppm of NaOCI solution to be titrated)

*NOTE: This equation may be used when analyzing for NaOCI or available chlorine. An approximate molecular weight for either available chlorine or NaOCI was included.

Transfer the approximate amount of sample (as calculated above) to at least three clean vessels. (An alternate number of replicates may be performed per Sponsor's request.) Transfer 10 mL of 10% KI solution and 10 mL of 10% H₂SO₄ to each vessel and mix the vessels. A dark yellow/brown color will emerge. Fill the buret with ~0.1N Sodium thiosulfate (the titrant). (An alternate normality of Sodium thiosulfate may be used where appropriate.) Begin adding the titrant to the vessel, mixing with additions. Continue adding the titrant until a pale yellow color emerges. Once the pale yellow color is achieved, add a few drops of starch indicator and mix. A dark blackish color will emerge. Continue titrating until a clear end-point is achieved. Read the volume of titrant added from the buret. Repeat this procedure for all remaining vessels. The actual ppm value will be determined by averaging the ppm results from each replicate. Results will rounded to the nearest whole ppm.

The test substance(s) will be tested as Ready-To-Use. At least three replicate pH determinations will be made. The pH measurements will be conducted at room temperature using a temperature compensating probe and a pH meter capable of measuring pH to \pm 0.05. At least two NIST traceable reference buffers surrounding the theoretical range will be used to calibrate the pH meter prior to sample analysis.

The results of the chemical tests from the test procedure section of this protocol will be reported in the final report.

CALCULATIONS

To calculate the available chlorine concentration (FAC):

ppm available CI = (mL titrant used) x (N of titrant) x (35.45 g Chlorine/Eq) x 1000 (actual sample weight in grams)

Once calculated, the ppm values for replicate titrations may be averaged and reported.

N of titrant = Normality of the Sodium thiosulfate using four significant digits (i.e. 0.1000N)

To calculate the percent hypochlorous acid (HOCL):

% HOCL = $100 \times [1 + K/(H^{+})]^{-1}$

Where: K_i is the dissociation constant of HOCL at 20°C or 2.621 x 10⁻⁸ mol/L (H⁺) is the negative log₁₀ if the average pH value per lot

To calculate the percent of available HOCL:

% Available HOC! = 100 x [% FAC x %HOC!]

STATISTICAL METHODS: Arithmetic averages and standard deviation will be used when applicable.

-- Proprietary Information --



Clarentis LLC Page 4 of 7 **ATS**LABS

REPORT

The final report will include but will not be limited to: the names of scientific supervisory personnel involved in the study, the dates of the study initiation and completion, the purpose as stated in the approved protocol, deviations from the protocol, a description of the test method, identification, description and storage of the test and control substances, and data interpretation which may include negative, positive or equivocal results.

PROTOCOL CHANGES

If it becomes necessary to make changes in the approved protocol, the revision and reasons for changes will be documented, reported to the Sponsor and will become a part of the permanent file for that study. Similarly, the Sponsor will be notified as soon as possible whenever an event occurs that may have an effect on the validity of the study.

Standard operating procedures used in this study will be the correct effective revision at the time of the work. Any minor changes to SOPs (for this study) or methods used will be documented in the raw data and approved by the Study Director.

PRODUCT DISPOSITION

It is the responsibility of the Sponsor to retain a sample of the test substance. All unused test substance will be discarded following study completion unless otherwise indicated by Sponsor.

RECORD RETENTION

Study Specific Documents

All of the original raw data developed exclusively for this study shall be archived at ATS Labs. These original data include, but are not limited to, the following:

- All handwritten raw data for control and test substances including, but not limited to, notebooks, data forms and calculations.
- 2. Any protocol amendments/deviation notifications.
- 3. All measured data used in formulating the final report.
- Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
- 5. Original signed protocol.
- Certified copy of final study report.
- 7. Study-specific SOP deviations made during the study.

Facility Specific Documents

The following records shall also be archived at ATS Labs. These documents include, but are not limited to, the following:

- 1. SOPs which pertain to the study conducted.
- Non study-specific SOP deviations made during the course of this study which may affect the results obtained during this study.
- 3. Methods which were used or referenced in the study conducted.
- 4. QA reports for each QA inspection with comments.
- Facility Records: Temperature Logs (ambient, incubator, etc.), Instrument Logs, Calibration and Maintenance Records.
- 6. Current curriculum vitae, training records, and job descriptions for all personnel involved in the study.

- Proprietary Information -

Project No. A09183

Protocol Number: CLS01030210.CUST.1

Clarentis LLC Page 21 of 23



Protocol Number: CLS01030210.CUST.1

Clarentis LLC Page 5 of 7 ATS&LABS

REFERENCES

- 1. ATS Labs SOP # CGT-0090, "Sodium Hypochlorite Preparation and Sodium Hypochlorite / Available Chlorine Determination", current version.
- Code of Federal Regulations, 40 CFR 158.
 Eaton AD, et. al. 2005. Standard Methods For the Examination of Water and Wastewater, 21st edition. Washington DC: American Public Health Association.
- 4. Handbook of Chemistry and Physics, CRC Publishing Co., Boca Raton, FL, 58th Edition.
- 5. ASTM E70-97, "Standard Test method for pH of Aqueous Solutions with the Glass Electrode", 2002.
- 6. ATS Labs SOP # PCT-8030, "pH Measurement", current version.

Project No. A09183
Protocol Number: CLS01030210.CUST.1

Clarentis LLC Page 22 of 23



03/04/2010 14:50 FAX 5617763106

2003

▲ Available chlorine Active Concentration of NaOCI or Available Chlorine (upo	should appear on final report): L-10 (11tra-Lyte UL-10, UL-11 UL-13 an	, UI d U
Froduct Description to be Evaluated: Capture Theoretical ppm of Pavailable Chlorine (upo		,UI du
Product Description to be Evaluated: ☐ Sodium hypochlorite Theoretical ppm of ☐ Available chlorine Active Concentration of NaOCI or Available Chlorine (upo		, UI d U
Product Description to be Evaluated: ☐ Sodium hypochlorite Theoretical ppm of ☐ Available chlorine Active Concentration of NaOCI or Available Chlorine (upo		u ا d U
Product Description to be Evaluated: ☐ Sodium hypochlorite Theoretical ppm of ☐ Available chlorine Active Concentration of NaOCI or Available Chlorine (upo		
☐ Sodium hypochlorite Theoretical ppm of Available chlorine Active Concentration of NaOCi or Available Chlorine (upo	on submission to ATS Labs):	
	on submission to ATS Labs): 0 ~500 ppm	
	0	٠
ype of Sample (circle one): Manufacturing Use	Product or (End-Use Product) or Active Ingredient	
itorage Conditions IX Room Temperature II 2-8°C II Other	O clarified per email dated 3/5/10 AST 3/9/10	
azards S None known: Use Standard Precautions Material Safety Data Sheet, Attached for each produc As Follows:	ict	
umber of Titration replicates per sample ☑ 3 replicates ☐ Other		
umber of pH replicates per sample ☑ 3 replicates ☑ Other		
•		

Clarentis LLC Page 23 of 23



03/04/2010 14:50 FAX 5617763106

Protocol Number: CLS01030210.CUST.1

Ø 002

	otocol Number: CLS01030210.CUST.1	Clarentis LLC Page 7 of 7	∧TS®L∧BS
TE	ST SUBSTANCE SHIPMENT STATUS		
0	Has been used in one or more previous studies at ATS Labs been shipped to ATS Labs (but has not been used in Date shipped to ATS Labs:	a previous study).	miaht delivery? 6 Yes 6 No
ď	Will be shipped to ATS Labs. Date of expected receipt at ATS Labs:	3-11-10	•
	Sender (if other than Sponsor):		
If t	DMPLIANCE the Sponsor chooses to conduct the study under GLP con- actice Standards), the study will be inspected during at lese a ATS Labs Quality Assurance unit.	npliance (EPA 40 C ast one critical phas	FR, Part 160 - Good Laboratory a and the final report audited by
	GLP: This study will be conducted per GLP regulations.		
٥	Non-GLP: This study will be non-GLP but will be con applicable ATS Labs standard operating process.	nducted to be comp edures.	pliant with this protocol and all
<u>PF</u>	ROTOCOL MODIFICATIONS		
<u>a</u>	Approved without modification Approved with modification - Supplemental Information Form	n Attached - 🖸 Yes	□ No
	ONSOR: Duke Van Kalken (Clarentis LLC)		President
SK	GNATURE: Jke un Kal	DATE:	3-3-10
_,			
	VANE: 561.827.4142 (cell) FAX: 561.709.9218	EMAIL:	dukevankalken@hotmail.com
PΗ	HONE: 561-827-4142 (cell) FAX: 561-799-9215 For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically auth	ed only to the sponso	r/representative signing the
PΗ	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically auth	ed only to the sponso norized in writing to re	r/representative signing the
PH	Cor confidentially numbers study information will be release	ed only to the sponso norized in writing to re	r/representative signing the ceive study information.
PH	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically auth Other individuals authorized to receive information regar	ed only to the sponso norized in writing to re	r/representative signing the ceive study information.
PH A1	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically authorized to receive information regardance. The Labs:	ed only to the sponso norized in writing to re	r/representative signing the ceive study information.
PH A1	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically auth Other individuals authorized to receive information regar	ed only to the sponso norized in writing to re	r/representative signing the ceive study information. 8 See Attached
PH NA	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically authorized to receive information regardance. TS Labs: STENSE Study Director GNATURE:	ed only to the sponso norized in writing to re rding this study:	r/representative signing the ceive study information.
PH NA	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically authorized to receive information regarded. TS Labs: Study Director	ed only to the sponso norized in writing to re rding this study:	n/representative signing the ceive study information. e See Attached
AT NA	For confidentiality purposes, study information will be release protocol (above) unless other individuals are specifically authorized to receive information regardance. TS Labs: STENSE Study Director GNATURE:	ed only to the sponso norized in writing to re rding this study:	n/representative signing the ceive study information. e See Attached